All Posts Tagged With: "GSK"
(HGSI) Human Genome Sciences Analyst Still Neutral on Shares
We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $8.25.
Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical...
(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a...
(ALNY) Alnylam Pharmaceuticals Analyst Still Bullish
We have maintained an Outperform rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $8.25 per share following appraisal of third quarter 2011 results.
Alnylam Pharmaceuticals Inc....
(EU) Emerging Markets: The Way Forward
According to Irish orator, philosopher, & politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well.
Until recently, most commercialization efforts were focused on the U.S....
(ISIS) Isis Pharmaceuticals Analyst Downgrades Shares to Neutral
We recently downgraded Isis Pharmaceuticals (ISIS) to Neutral from an Outperform recommendation. Isis Pharma is a drug discovery and development company that focuses on the development of products using ribonucleic...
(MYL) Mylan Settles with Novartis
Mylan, Inc. (MYL) recently announced a settlement agreement with Novartis (NVS) relating to the generic version of Novartis’ bioidentical...
(THRX) Theravance Third Quarter Loss Deteriorates
Theravance Inc.’s (THRX) third quarter 2011 loss per share of 37 cents was wider than the Zacks Consensus loss Estimate of 33 cents as well as the year-ago loss of 29 cents per share. The wider loss was...
(VRTX) Vertex Pharmaceuticals Riding High on Incivek Sales
Vertex Pharmaceuticals Inc. (VRTX) posted robust third quarter 2011 earnings (including stock-based compensation expense) of 56 cents per share, substantially above the Zacks Consensus Estimate of 19 cents...
(EU) Pharmaceuticals Stock Outlook – September 2011 – Industry Outlook
The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance...
(VVUS) Vivus’ Erectile Dysfunction Drug Presents Positive Data
Vivus Inc. (VVUS) recently presented positive data from a late-stage trial on its erectile dysfunction (ED) candidate, avanafil, at the 47th European Association for the Study of Diabetes Annual Meeting....
(ALKS) Alkermes Analyst Maintains Neutral Rating on Shares
We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS). Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the...
(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares
We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share.
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics...
(HGSI) Human Genome Sciences Analyst Maintains Neutral Recommendation
We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $16.00.
Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical...
(ONXX) Onyx Analyst Downgrades Shares to Underperform
We recently downgraded our recommendation on Onyx Pharmaceuticals, Inc. (ONXX) to Underperform from Neutral.
We note that Onyx Pharma’s second quarter 2011 loss of 56 cents was well below expectations,...
(VVUS) Vivus’ Loss Narrowed Due To Lower Spend
Vivus Inc. (VVUS) posted adjusted loss of 14 cents per share during the second quarter of fiscal 2011, in line with the Zacks Consensus Estimate. However, the loss was narrower than the year-ago loss of 27...
(VRX) Valeant Pharmaceuticals International Beats Expectations – Ups View
Valeant Pharmaceuticals International’s (VRX) second quarter 2011 earnings of 68 cents per share (excluding special items but including stock based compensation expense) beat the Zacks Consensus Estimate...
(VRTX) Vertex Pharmaceuticals Loss Reduced by Incivek
Vertex Pharmaceuticals Inc. (VRTX) posted second quarter 2011 loss (including stock-based compensation expense) of 82 cents per share, narrower than the Zacks Consensus Estimate of 93 cents and the year-ago...
(RDY) Dr. Reddy’s Laboratories Earns FDA Approval for Generic
Dr. Reddy’s Laboratories (RDY) delivered yet another positive momentum within a week, as the US Food and Drug Administration (FDA) approved fondaparinux sodium injection, the company’s bioequivalent generic...
(WPI) Watson Pharmaceuticals Entangled in Legal Dispute
The legal tussle between Watson Pharmaceuticals Inc. (WPI) and Shire plc (SHPGY) intensified, with the latter filing a patent infringement...
(WPI) Watson Pharmaceuticals Files More Abbreviated New Drug Applications
Watson Pharmaceuticals Inc. (WPI) recently announced that it has filed Abbreviated New Drug Applications (ANDA) with the US Food and Drug Administration (FDA) to market its generic version of GlaxoSmithKline...
(AMGN) Amgen Seeks Label Expansion
Amgen (AMGN) is looking to gain approval for additional indications of Xgeva. The company recently submitted a supplemental Biologics License Application (sBLA) seeking US Food and Drug Administration (FDA)...
(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral on Shares
We have maintained a Neutral rating on Alnylam Pharmaceuticals Inc. (ALNY) with a target price of $9.50 per share.
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics...
(VVUS) Vivus’ Erectile Dysfunction Drug on Track
Vivus Inc. (VVUS) recently reported positive results from a late-stage trial, REVIVE-RP (TA-303), on avanafil. The study evaluated the safety and efficacy of avanafil in the treatment of erectile dysfunction...
(PFE) Pfizer’s Chantix Could Increase Heart Risk
The US Food and Drug Administration (FDA) recently announced that Pfizer’s (PFE) smoking cessation aid Chantix (varenicline) could be linked with a small, increased risk of certain cardiovascular adverse...
(EU) UCB Reports Data on Neupro
UCB (UCBJF) recently reported results from post hoc analyses of its restless legs syndrome (RLS) treatment Neupro (rotigotine). The data were presented at the International Congress of Parkinson’s disease...
(THRX) Theravance Analyst Maintains Neutral on Shares
We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results.
Theravance’s first...
(JNJ) Pharma & Biotech Stock Outlook – June 2011 – Industry Outlook
Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between...
(THRX) Theravance Analyst Maintains Neutral Rating on Shares
We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results.
Theravance’s first...
(RDY) Dr. Reddy’s Laboratories Continues to Grow
Dr. Reddy’s Laboratories (RDY) reported fiscal 2011 earnings per American Depositary Share (ADS) of $1.50 compared with 10 cents per ADS posted in fiscal 2010. Higher revenues and lower operating expenses...
(CRM) Salesforce-Toyota Make Allies
Salesforce.com Inc. (CRM) recently announced a strategic alliance with the multinational automobile manufacturer Toyota Motors Corp. (TM)....